Status:
UNKNOWN
Endothelial Activation Hemostasis Disturbances and Severe Bleeding Events in Hyperleukocytic Acute Myeloid Leukemia
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Leukemia, Myeloid, Acute
Eligibility:
All Genders
18-65 years
Brief Summary
Hyper-leukocytosis \> 50.109/L is observed in 15% of acute myeloid leukemia (AML). Level of hyper-leukocytosis is linearly associated with the incidence of life threatening complications that lead to...
Eligibility Criteria
Inclusion
- De novo AML
- GB counts \> 50 G/L
- Eligible for intensive chemotherapy
- no previous AML treatment
Exclusion
- secondary AML
- relapse of AML
- Acute promyelocytic leukemia
- Previous antiplatelet or anticoagulant treatment
Key Trial Info
Start Date :
October 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2022
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04133220
Start Date
October 1 2019
End Date
July 1 2022
Last Update
October 21 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.